Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 4/20 | 0.44 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | CPN1 | P15169 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446601 | 1.00 | SLC6A1 (0.44) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL4523217 | 1.00 | SLC6A1 (0.44) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL15549279 | 0.98 | EPHX1 (0.43) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL6958695 | 0.98 | EPHX1 (0.43) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL31041002 | 0.98 | EPHX1 (0.43) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL1876593 | 0.94 | SLC6A1 (0.42) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL15930224 | 0.90 | SLC6A1 (0.56) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL30455767 | 0.88 | SLC6A1 (0.55) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL6102502 | 0.88 | SLC6A1 (0.55) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL8414225 | 0.87 | POLB (0.41) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-10 | — | — | US | disclosed |
| US-12134609-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-117886814-A | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-03-21 | — | — | US | disclosed |
| CN-117447450-A | Triazole compounds and their use as LPAR1 antagonists | 武汉人福创新药物研发中心有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-5874428-A | A DRUG TREATING DIABETIC NEUROPATHY, MIGRAINE, NEUROGENIC INFLAMMATION OR RHEUMATOID ARTHRITIS | NOVO NORDISK ALS (DK) | 1999-02-23 | — | — | US | disclosed |
| WO-1998054179-A1 | PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-12-03 | — | — | WO | disclosed |
| EP-0871442-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5776931-A | TREATING PHYSIOLOGICAL DISORDER ASSOCIATED WITH EXCESS OF NEUROPEPTIDE Y | ELI LILLY AND COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0820451-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | disclosed |
| EP-0789688-A4 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0789688-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997025041-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
| WO-1997009308-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
| WO-1996031498-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | SLC6A1 1830/4885SLC6A11 1559/4885SLC6A13 2194/4885 |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | SLC6A1 1830/4885SLC6A11 1559/4885SLC6A13 2194/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | SLC6A1 1830/4885SLC6A11 1559/4885SLC6A13 2194/4885 |
| US-12134609-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | SLC6A1 1830/4885SLC6A11 1559/4885SLC6A13 2194/4885 |
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | POLRMT, TFAM, UQCRC1 | SLC6A1 4170/4885SLC6A11 4375/4885SLC6A13 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.